As of 2024-11-14, the Relative Valuation of SAGE Therapeutics Inc (SAGE) is (164.46) USD. This relative valuation is based on P/E multiples. With the latest stock price at 5.73 USD, the upside of SAGE Therapeutics Inc based on Relative Valuation is -2970.2%.
The range of the Relative Valuation is (168.77) - (172.74) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
Range | Selected | |
Trailing P/E multiples | 30.6x - 46.5x | 38.3x |
Forward P/E multiples | 21.3x - 31.3x | 21.3x |
Fair Price | (168.77) - (172.74) | (164.46) |
Upside | -3045.4% - -3114.7% | -2970.2% |
Date | P/E |
2024-11-08 | -1.14 |
2024-11-07 | -1.15 |
2024-11-06 | -1.08 |
2024-11-05 | -1.08 |
2024-11-04 | -1.05 |
2024-11-01 | -1.10 |
2024-10-31 | -1.10 |
2024-10-30 | -1.17 |
2024-10-29 | -1.54 |
2024-10-28 | -1.55 |
2024-10-25 | -1.45 |
2024-10-24 | -1.42 |
2024-10-23 | -1.39 |
2024-10-22 | -1.39 |
2024-10-21 | -1.41 |
2024-10-18 | -1.37 |
2024-10-17 | -1.31 |
2024-10-16 | -1.32 |
2024-10-15 | -1.24 |
2024-10-14 | -1.23 |
2024-10-11 | -1.19 |
2024-10-10 | -1.15 |
2024-10-09 | -1.18 |
2024-10-08 | -1.17 |
2024-10-07 | -1.22 |
2024-10-04 | -1.20 |
2024-10-03 | -1.27 |
2024-10-02 | -1.26 |
2024-10-01 | -1.26 |
2024-09-30 | -1.31 |
2024-09-27 | -1.32 |
2024-09-26 | -1.30 |
2024-09-25 | -1.27 |
2024-09-24 | -1.32 |
2024-09-23 | -1.31 |
2024-09-20 | -1.36 |
2024-09-19 | -1.43 |
2024-09-18 | -1.38 |
2024-09-17 | -1.36 |
2024-09-16 | -1.37 |
2024-09-13 | -1.42 |
2024-09-12 | -1.33 |
2024-09-11 | -1.36 |
2024-09-10 | -1.33 |
2024-09-09 | -1.35 |
2024-09-06 | -1.36 |
2024-09-05 | -1.38 |
2024-09-04 | -1.45 |
2024-09-03 | -1.43 |
2024-08-30 | -1.53 |